Skip to main content
main-content

28.09.2016 | Original Article – Cancer Research | Ausgabe 2/2017

Journal of Cancer Research and Clinical Oncology 2/2017

Gli1, a potential regulator of esophageal cancer stem cell, is identified as an independent adverse prognostic factor in esophageal squamous cell carcinoma

Zeitschrift:
Journal of Cancer Research and Clinical Oncology > Ausgabe 2/2017
Autoren:
Zhaoting Yang, Yan Cui, Weidong Ni, Seokhyung Kim, Yanhua Xuan
Wichtige Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1007/​s00432-016-2273-6) contains supplementary material, which is available to authorized users.
Zhaoting Yang and Yan Cui have contributed equally to this work.

Abstract

Purpose

The hedgehog (Hh) pathway is involved in cancer stem cell (CSC) maintenance in various tumors. Glioma-associated oncogene homolog 1 (Gli1) is a key mediator of the Hh pathway; however, its expression and clinical significance in esophageal squamous cell carcinoma (ESCC) have not been reported. In this study, we aimed to reveal clinical significance of Gli1 expression in ESCC and further investigate the potential of Gli1 as a CSC regulator of ESCC by comparing its expression with expressions of other stemness genes in ESCC.

Methods

We assessed the expressions of Gli1, Sox9, CD44, Sox2, LSD1, and Oct4 in 127 patients’ tissue specimens of ESCC using immunohistochemistry and in ESCC cell lines using Western blotting. The relationship of Gli1 expression with clinic–pathologic parameters as well as cell-cycle-regulating genes was investigated. We also investigated the biological pathways that are activated in Gli1-high ESCC using The Cancer Genome Atlas (TCGA) data.

Results

Gli1 expression was observed in 28.3 % of ESCC, and its expression was correlated with the expression of stemness genes, Sox9 (P = 0.003) and CD44 (P = 0.012). And Gli1, CD44, and Sox9 were highly expressed in more poorly differentiated ESCC cell lines such as TE8 and TE1 cells. Notably, Gli1 expression was positively associated with distant metastasis (P = 0.011), increased microvessel density (MVD) (P = 0.002), and expression of cell cycle regulators such as p21, cyclin D1, cyclin E1, and NF-κB (P < 0.05). Sox9 and CD44 expressions in ESCC were also significantly associated with unfavorable clinic–pathologic parameters such as increased MVD, advanced tumor (pT) stage, and higher TNM stage. Moreover, all three potential CSC markers such as Gli1, Sox9, and CD44 were strongly linked to worse clinical outcome and independent poor prognostic factors in overall survival and disease-free survival in ESCC. Gene set enrichment analysis revealed that the Gli1-high-expressing ESCC patients’ group was strongly enriched for gene expression signature of Hh signaling pathway, epithelial–mesenchymal transition, and cancer stem cell.

Conclusions

Targeting Gli1, a potential diagnostic marker of ESCC stem cells, will have a profound therapeutic and prognostic value.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

★ PREMIUM-INHALT
e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de. Zusätzlich können Sie eine Zeitschrift Ihrer Wahl in gedruckter Form beziehen – ohne Aufpreis.

Weitere Produktempfehlungen anzeigen
Zusatzmaterial
Supplementary Fig. 1 Immunohistochemical staining of ESCC with LSD1, Sox2 and Oct4. Kaplan–Meier analyses of overall and disease-free survival curves for LSD1 (a and d), Sox2 (b and e) and Oct4 (c and f) expression in ESCC patients. (TIFF 12649 kb)
432_2016_2273_MOESM1_ESM.tif
Supplementary Fig. 2 Western blot analysis of LSD1, Sox2, and Oct44 in ESCC cells line. β-Actin was used as a loading control. (TIFF 1219 kb)
432_2016_2273_MOESM2_ESM.tif
Supplementary material 3 (DOC 126 kb)
432_2016_2273_MOESM3_ESM.doc
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 2/2017

Journal of Cancer Research and Clinical Oncology 2/2017 Zur Ausgabe
  1. Sie können e.Med Innere Medizin 14 Tage kostenlos testen (keine Print-Zeitschrift enthalten). Der Test läuft automatisch und formlos aus. Es kann nur einmal getestet werden.

  2. Das kostenlose Testabonnement läuft nach 14 Tagen automatisch und formlos aus. Dieses Abonnement kann nur einmal getestet werden.

Neu im Fachgebiet Onkologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise